Carregant...
Suppression of autophagy by BCR/ABL
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a “reservoir” o...
Guardat en:
| Publicat a: | Leuk Lymphoma |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416844/ https://ncbi.nlm.nih.gov/pubmed/21250825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.546913 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|